JP2023098947A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2023098947A5 JP2023098947A5 JP2023061595A JP2023061595A JP2023098947A5 JP 2023098947 A5 JP2023098947 A5 JP 2023098947A5 JP 2023061595 A JP2023061595 A JP 2023061595A JP 2023061595 A JP2023061595 A JP 2023061595A JP 2023098947 A5 JP2023098947 A5 JP 2023098947A5
- Authority
- JP
- Japan
- Prior art keywords
- use according
- antagonist
- composition
- fibrosis
- senescent cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17382417.8 | 2017-06-29 | ||
| EP17382417.8A EP3421607A1 (en) | 2017-06-29 | 2017-06-29 | Identification and elimination of damaged and/or senescent cells |
| JP2019572038A JP2020525021A (ja) | 2017-06-29 | 2018-06-29 | 損傷および／または老化細胞の同定および排除 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019572038A Division JP2020525021A (ja) | 2017-06-29 | 2018-06-29 | 損傷および／または老化細胞の同定および排除 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023098947A JP2023098947A (ja) | 2023-07-11 |
| JP2023098947A5 true JP2023098947A5 (https=) | 2024-03-25 |
Family
ID=59315550
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019572038A Pending JP2020525021A (ja) | 2017-06-29 | 2018-06-29 | 損傷および／または老化細胞の同定および排除 |
| JP2023061595A Pending JP2023098947A (ja) | 2017-06-29 | 2023-04-05 | 損傷および／または老化細胞の同定および排除 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019572038A Pending JP2020525021A (ja) | 2017-06-29 | 2018-06-29 | 損傷および／または老化細胞の同定および排除 |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US20200123607A1 (https=) |
| EP (2) | EP3421607A1 (https=) |
| JP (2) | JP2020525021A (https=) |
| CA (1) | CA3068363A1 (https=) |
| WO (1) | WO2019002581A1 (https=) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112996805A (zh) | 2018-08-30 | 2021-06-18 | Hcw生物科技公司 | 多链嵌合多肽和其用途 |
| EP3843788A1 (en) | 2018-08-30 | 2021-07-07 | HCW Biologics, Inc. | Single-chain chimeric polypeptides and uses thereof |
| JP7713393B2 (ja) | 2019-06-21 | 2025-07-25 | イミュニティーバイオ インコーポレイテッド | 多鎖キメラポリペプチドおよびその使用 |
| US12115191B2 (en) | 2020-02-11 | 2024-10-15 | Immunitybio, Inc. | Methods of treating age-related and inflammatory diseases |
| KR20220140535A (ko) | 2020-02-11 | 2022-10-18 | 에이치씨더블유 바이올로직스, 인크. | 크로마토그래피 수지 및 이의 용도 |
| EP4103599A1 (en) | 2020-02-11 | 2022-12-21 | HCW Biologics, Inc. | Methods of activating regulatory t cells |
| EP4143231A1 (en) | 2020-04-29 | 2023-03-08 | HCW Biologics, Inc. | Anti-cd26 proteins and uses thereof |
| US12024545B2 (en) * | 2020-06-01 | 2024-07-02 | HCW Biologics, Inc. | Methods of treating aging-related disorders |
| EP4431102A4 (en) * | 2021-11-10 | 2025-10-29 | Lifeceutix Co Ltd | Senescent Cell Elimination Compositions and Their Uses |
| CN114836508A (zh) * | 2021-12-08 | 2022-08-02 | 上海锐翌医学检验实验室有限公司 | 慢性阻塞性肺病标志微生物及其应用 |
| EP4486457A1 (en) | 2022-03-04 | 2025-01-08 | Rejuveron Senescence Therapeutics AG | Anti pd-l2 antibody |
| EP4507711A1 (en) | 2022-04-13 | 2025-02-19 | ImmunityBio, Inc. | Multi-chain chimeric polypeptide for use in the treatment of treating neuroinflammatory disorder |
| JPWO2023238845A1 (https=) * | 2022-06-07 | 2023-12-14 | ||
| CN115154611B (zh) * | 2022-06-23 | 2023-11-17 | 中山大学孙逸仙纪念医院 | 免疫检查点抑制剂与抗衰老药物联合在制备肿瘤治疗产品中的用途 |
| WO2024063109A1 (ja) * | 2022-09-20 | 2024-03-28 | 国立大学法人東京大学 | 老化細胞除去剤 |
| KR20260008114A (ko) * | 2023-05-04 | 2026-01-15 | (주)라이프신약 | 노화세포 제거 또는 억제용 조성물 및 이의 용도 |
| WO2024249938A1 (en) * | 2023-05-31 | 2024-12-05 | Mayo Foundation For Medical Education And Research | Methods and materials for identifying and treating senescence/age-related diseases |
| WO2025051889A1 (en) * | 2023-09-06 | 2025-03-13 | Rejuveron Senescence Therapeutics Ag | Anti pd-l2 antibodies for use in treating fibrotic diseases |
| CN120960439A (zh) * | 2025-10-14 | 2025-11-18 | 中南大学湘雅医院 | Usp51的抑制剂与pd-l1/pd-1单抗药物联用在制备肿瘤免疫治疗药物中的应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| AU2005248958A1 (en) * | 2000-06-28 | 2006-02-02 | Brigham And Women's Hospital | PD-L2 molecules: novel PD-1 ligands and uses therefor |
| EP1320599A2 (en) * | 2000-06-28 | 2003-06-25 | Genetics Institute, LLC | Pd-l2 molecules: pd-1 ligands and uses therefor |
| SG11201606428UA (en) * | 2014-02-04 | 2016-09-29 | Incyte Corp | Combination of a pd-1 antagonist and an ido1 inhibitor for treating cancer |
| WO2016134416A1 (en) * | 2015-02-23 | 2016-09-01 | The University Of Queensland | A method for assessing prognosis of lymphoma |
| JP2018515474A (ja) * | 2015-04-28 | 2018-06-14 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | 抗ｐｄ−１抗体を使用するｐｄ−ｌ１陽性黒色腫の処置 |
| RU2733033C2 (ru) * | 2015-06-24 | 2020-09-28 | Иммодьюлон Терапьютикс Лимитед | Ингибитор контрольных точек и целые клетки микобактерий для применения в терапии рака |
| WO2017053250A1 (en) * | 2015-09-21 | 2017-03-30 | Merck Sharp & Dohme Corp. | Antibody that binds to human programmed death ligand 2 (pd-l2) and uses thereof |
-
2017
- 2017-06-29 EP EP17382417.8A patent/EP3421607A1/en not_active Withdrawn
-
2018
- 2018-06-29 US US16/627,034 patent/US20200123607A1/en not_active Abandoned
- 2018-06-29 JP JP2019572038A patent/JP2020525021A/ja active Pending
- 2018-06-29 EP EP18735568.0A patent/EP3645746A1/en not_active Withdrawn
- 2018-06-29 WO PCT/EP2018/067655 patent/WO2019002581A1/en not_active Ceased
- 2018-06-29 CA CA3068363A patent/CA3068363A1/en active Pending
-
2023
- 2023-04-05 JP JP2023061595A patent/JP2023098947A/ja active Pending
-
2024
- 2024-06-21 US US18/750,834 patent/US20240344128A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023098947A5 (https=) | ||
| Galsky et al. | Gemcitabine, cisplatin, and sunitinib for metastatic urothelial carcinoma and as preoperative therapy for muscle-invasive bladder cancer | |
| Katoh | Genomic testing, tumor microenvironment and targeted therapy of Hedgehog-related human cancers | |
| Khanna et al. | Ongoing clinical trials and treatment options for patients with systemic sclerosis–associated interstitial lung disease | |
| Kim et al. | Cyclophosphamide in dermatology | |
| JP6066421B2 (ja) | 癌の治療のための低酸素活性化プロドラッグおよび血管新生阻害剤の投与方法 | |
| JP2017522307A5 (https=) | ||
| JP7142200B2 (ja) | ＭＡｄＣＡＭアンタゴニストの投与レジメン | |
| JP2017537090A5 (https=) | ||
| Kuwana et al. | Nintedanib: New indication for systemic sclerosis-associated interstitial lung disease | |
| JP2014533279A5 (https=) | ||
| JP2017514795A5 (https=) | ||
| JP2017537105A (ja) | 瘻孔を伴うクローン病の治療用ベドリズマブ | |
| JP2017501167A5 (https=) | ||
| JP2016536361A5 (https=) | ||
| JP2017113019A5 (https=) | ||
| JP2019505527A5 (https=) | ||
| JP2020511408A5 (https=) | ||
| JP2019533651A5 (https=) | ||
| JP2019525948A5 (https=) | ||
| KR20230098279A (ko) | Pdx 억제제 또는 독소루비신과 ahr 억제제의 조합 | |
| JP2014532648A5 (https=) | ||
| WO2017165742A1 (en) | Methods of treating gastrointestinal immune-related adverse events in anti-ctla4 anti-pd-1 combination treatments | |
| JP2025508131A5 (https=) | ||
| JP2017527615A5 (https=) |